M&A / Deals Gilead strikes again, penning $5bn deal to buy Tubulis PharmaphorumGilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaphorum Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront. M&A / DealsRead full story Post navigation Previous: AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat SolidifiesNext: 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
